NCCN Recommends Ropeginterferon Alfa-2B as First-Line Cytoreductive Therapy for PV
Ropeginterferon alfa-2b has been listed as a preferred first-line cytoreductive therapy by the National Comprehensive Cancer Network for patients with polycythemia vera.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with lisocabtagene maraleucel experienced durable responses.
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
Patients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.
Ruxolitinib Cream Improves Body Surface Area in Cutaneous GVHD
Compared with placebo, ruxolitinib cream significantly improved body surface area in patients with cutaneous graft-vs-host disease in a phase 2 trial.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
2 Commerce Drive Cranbury, NJ 08512